Bleeding Events Associated with Novel Anticoagulants: A Case Series

Mirzaee, S.; Tran, Tara Thi Thien; Amerena, John

doi:10.1016/j.hlc.2013.04.115

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 Warfarin (Coumadin s ; Bristol-Myers Squibb, New York, NY, USA) has been the predominant OAC prescribed for stroke prevention in patients with non-valvular AF. 4,5 Its disadvantages, however, include a narrow therapeutic index, a potential for interaction with other drugs, and the need for frequent monitoring of international normalized ratio. Dabigatran etexilate (Pradaxa s ; Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany) was the first direct OAC approved by the United States (US) Food and Drug Administration in 2010 to reduce the risk of stroke in AF patients.…”

Section: Management Of Af and Strokementioning

confidence: 99%

The Use of Electronic Personal Health Records to Improve Medication Adherence and Patient Engagement: A Randomized Study of Non-valvular Atrial Fibrillation Patients

Chen¹,

Roebuck²,

Sami³

et al. 2017

J Innov Cardiac Rhythm Manage

View full text Add to dashboard Cite

ABSTRACT. Embolic stroke is a major complication of atrial fibrillation (AF) that frequently results in disability or death. The administration of oral anticoagulation can reduce stroke risk in AF patients; however, medication non-adherence can eliminate this benefit. To date, reported patient adherence rates to oral anticoagulation regimens vary. The objective of the current study was to examine the impact of medication-specific education delivered via a personal health record (PHR) system on medication adherence. A randomized, prospective study was conducted from February 2014 to June 2014 at Parkview Health, a not-for-profit, community-based health care clinic that serves a northeastern Indiana population of more than 820,000. AF patients receiving dabigatran (Pradaxa s ; Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany) to prevent stroke participated in this study. The study participants were predominantly Caucasian males over 65 years of age who were educated, insured, and living above the poverty level. Patients were allowed to view online, download, and transmit health information via a PHR. The intervention group received PHR training and dabigatran education via the PHR. The control group received standard care and PHR access without training. A longitudinal survey pertaining to medication knowledge, medication adherence, and patient engagement was administered at baseline and at the end of the study. Medication-dispensing data collected from pharmacy refill prescriptions were used for calculating the medication possession ratio (MPR). Ninety patients were included in this study, and were randomly assigned to either the intervention group (n ¼ 46) or the control group (n ¼ 44). All participants completed the baseline survey, and 95.6% of patients finished the follow-up survey. The mean score for knowledge increased significantly in the intervention group (from 3.77 to 4.23, p ¼ 0.005), but not in the control group (from 3.70 to 3.95, p ¼ 0.72). The MPR was significantly higher in the intervention group (97.47% vs. 87.67%, p ¼ 0.001). Both groups had similar levels of improvement in Patient Activation Measure scores (from 63.0 to 65.8, p ¼ 0.078 vs. from 63.1 to 63.6, p ¼ 0.814). Patients who used the PHR achieved greater medication knowledge, resulting in improved medication adherence. To our knowledge, no published randomized trial has reported on the use of PHRs to improve medication adherence and knowledge. This study is the first to demonstrate a positive impact on anticoagulation adherence with PHR use.

show abstract

Section: Management Of Af and Strokementioning

confidence: 99%